Anesth Analg 2003;97:680-683
© 2003 International Anesthesia Research Society
CARDIOVASCULAR ANESTHESIA
Binding of Hydroxyethyl Starch Molecules to the Platelet Surface
Engelbert Deusch, MD,
Thomas Gamsjäger, MD,
Hans-Georg Kress, MD PhD, and
Sibylle A. Kozek-Langenecker, MD
Department of Anesthesiology and Intensive Care (B), University of Vienna, School of Medicine, Vienna, Austria
Address correspondence and reprint requests to Engelbert Deusch, MD, Department of Anesthesiology and Intensive Care, University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria. Address e-mail to e.deusch{at}utanet.at
Hydroxyethyl starch (HES) solutions impair platelet function by reducing the availability of the fibrinogen receptor. This effect is not mediated by intracellular signal transduction pathways. Also, an unspecific coating of platelets by HES macromolecules may be responsible for its antiplatelet effects. To test this hypothesis, we investigated the binding of fluorochrome-coupled HES to the surface of human platelets using whole blood flow cytometry. Citrated whole blood from 8 volunteers was incubated (5 min, 22°C, in the dark) with fluorescein isothiocyanate (FITC)-coupled HES (200-kDa molecular weight, 0.5 degree of substitution, 0.042 molar ratio of FITC-conjugation) resulting in 0%, 1%, 3%, 5%, 10%, 20%, and 40% hemodilution. The percentage of platelets binding FITC-HES was determined using a FACSCaliburTM flow cytometer and CellQuestProTM software. The percentage of FITC-positive platelets increased in a concentration-dependent manner reaching statistical significance at 10% hemodilution. Binding was independent of fibrinogen receptor blockade. The present experiments clearly demonstrate that extracellular binding of HES to the platelet surface is, at least in part, responsible for the antiplatelet effects of HES by blocking the access of ligands to the platelet fibrinogen receptor.
IMPLICATIONS: Hydroxyethyl starch solutions are widely used for fluid replacement in patients undergoing surgery but may compromise blood coagulation. The present study demonstrates that one of the mechanisms for this unwanted side effect is related to the binding of hydroxyethyl starch to the outer surface of blood platelets.
This article has been cited by other articles:

|
 |

|
 |
 
S. A. Kozek-Langenecker, C. Jungheinrich, W. Sauermann, and P. Van der Linden
The Effects of Hydroxyethyl Starch 130/0.4 (6%) on Blood Loss and Use of Blood Products in Major Surgery: A Pooled Analysis of Randomized Clinical Trials
Anesth. Analg.,
August 1, 2008;
107(2):
382 - 390.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. von Roten, C. Madjdpour, P. Frascarolo, M.-A. Burmeister, A. Fisch, S. Schramm, T. Bombeli, and D. R. Spahn
Molar substitution and C2/C6 ratio of hydroxyethyl starch: influence on blood coagulation
Br. J. Anaesth.,
April 1, 2006;
96(4):
455 - 463.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Madjdpour, N. Dettori, P. Frascarolo, M. Burki, M. Boll, A. Fisch, T. Bombeli, and D. R. Spahn
Molecular weight of hydroxyethyl starch: is there an effect on blood coagulation and pharmacokinetics?
Br. J. Anaesth.,
May 1, 2005;
94(5):
569 - 576.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Deusch, U. Thaler, and S. A. Kozek-Langenecker
The Effects of High Molecular Weight Hydroxyethyl Starch Solutions on Platelets
Anesth. Analg.,
September 1, 2004;
99(3):
665 - 668.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|